Shalby Swings to ₹18.3 Cr Q4 Profit as EBITDA Margins Jump to 10.2%

Market snapshot: Shalby Limited has delivered a sharp financial turnaround in the final quarter of FY26, transitioning from a net loss to a double-digit crore profit. The results underscore a significant recovery in operational efficiency and surgical volumes across its multispecialty hospital network.

Data Snapshot

• Q4 Revenue: ₹290 crore (Up 11.5% YoY)
• Net Profit: ₹18.3 crore (vs ₹11 crore loss YoY)
• EBITDA: ₹29.3 crore (Up 40.2% YoY)
• EBITDA Margin: 10.20% (vs 7.89% YoY)

What's Changed

• Profitability: Swung from a loss-making state to a positive PAT of ₹18.3 crore.
• Margin Trajectory: Expanded operating margins by 231 basis points through better cost management.
• Revenue Base: Increased top-line by ₹30 crore compared to the previous year's quarter.

Key Takeaways

• The turnaround is primarily driven by a recovery in high-margin surgical volumes and orthopedic procedures.
• Operational leverage is kicking in as EBITDA growth (40.2%) outpaced revenue growth (11.5%).
• Diversification into the MedTech segment is likely contributing to improved consolidated yields.

SAHI Perspective

Shalby's shift back to profitability is a critical milestone for its post-pandemic structural recovery. By optimizing occupancy levels (currently around 48%) and scaling its MedTech division, the company is moving toward a more sustainable and balanced revenue mix. The margin expansion to 10.2% is healthy, but remains sensitive to specialist doctor attrition and insurance negotiation cycles.

Market Implications

The hospital sector is seeing a broad-based recovery in inpatient volumes. For Shalby, the successful turnaround validates its leadership in the orthopedic franchise model. Capital allocation is likely to shift toward further expanding its SOCE (Shalby Orthopedics Centers of Excellence) across North and West India.

Trading Signals

Market Bias: Bullish

The sharp swing to a ₹18.3 crore profit and 231 bps margin expansion signals a fundamental trend reversal and improved operational health.

Overweight: Healthcare, Hospitals, MedTech

Trigger Factors:

• Bed occupancy reaching above 50%
• Scaling of MedTech (implant) revenue
• New unit operationalization in Gujarat

Time Horizon: Near-term (0-3 months)

Industry Context

The Indian healthcare sector is benefiting from increased insurance penetration and a rise in elective surgeries that were deferred in previous years. Shalby’s niche in arthroplasty provides a defensive moat against generic multispecialty competition.

Key Risks to Watch

• Dependence on high-end specialist retention.
• Sensitivity to regulatory pricing caps on medical implants.
• Potential friction in renewal of major insurance and TPA contracts.

Recent Developments

On April 9, 2026, Shalby received a 5-year regulatory approval for kidney transplant services at its Krishna unit in Ahmedabad. In March 2026, the company inaugurated a new oncology and radiotherapy wing in Surat, further diversifying its specialized service portfolio.

Closing Insight

Shalby's Q4 performance marks a decisive return to profitability, positioning the stock for a potential re-rating if margin expansion remains consistent through FY27.

FAQs

What was the main driver for Shalby's profit turnaround in Q4?

The turnaround was driven by an 11.5% growth in revenue to ₹290 crore and a 231 basis point expansion in EBITDA margins, signaling better cost efficiency and recovery in surgery volumes.

How did Shalby's MedTech segment perform this quarter?

While specific quarterly revenue for MedTech wasn't in the main alert, recent trends show a 45% YoY growth in this segment, which is increasingly contributing to the company's 10.2% operating margins.

What does the kidney transplant approval in Ahmedabad mean for future revenue?

This 5-year regulatory approval allows Shalby to offer high-acuity, high-realization services, which typically command higher margins and drive longer average patient stays (ARPOB).

High Performance Trading with SAHI.